Global Market for Erythropoietin: 2015-2020

Report Code: ACP-17-667 | Page Numbers: 110

This market research report explain current market for erythropoietin drugs in terms of value. The report also highlights the major drivers and challenges, including their profiles related to erythropoietin drugs.

The global market for erythropoietin drugs has been growing at a CAGR (2015 to 2020) of 1.0% driven by the increasing cases of anemia particularly in kidney diseases and cancer globally.

The global market for erythropoietin drugs is expected to grow from $7.0 billion in 2014 to $7.4 billion in 2015 at a year-on-year (YOY) growth rate of 5.1%. In addition, the market is expected to grow at a five-year CAGR (2015 to 2020) of 1.0%, to reach $7.8 billion in 2020.

The major players in the biologic erythropoietin drug market are, Amgen, Inc., Johnson & Johnson and Hoffmann-LA Roche. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer, Inc.), Biocon, Biosidus, 3SBio, are some of the major biosimilar players across regions. ...

Buy Now

"Get Notified On all out New and Upcoming Reports"

       on all the latest research reports

This market research report explain current market for erythropoietin drugs in terms of value. The report also highlights the major drivers and challenges, including their profiles related to erythropoietin drugs.

The global market for erythropoietin drugs has been growing at a CAGR (2015 to 2020) of 1.0% driven by the increasing cases of anemia particularly in kidney diseases and cancer globally.

The global market for erythropoietin drugs is expected to grow from $7.0 billion in 2014 to $7.4 billion in 2015 at a year-on-year (YOY) growth rate of 5.1%. In addition, the market is expected to grow at a five-year CAGR (2015 to 2020) of 1.0%, to reach $7.8 billion in 2020.

The major players in the biologic erythropoietin drug market are, Amgen, Inc., Johnson & Johnson and Hoffmann-LA Roche. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer, Inc.), Biocon, Biosidus, 3SBio, are some of the major biosimilar players across regions.
CHAPTER: ONE

INTRODUCTION OBJECTIVES SCOPE
DATA SOURCES DISCLAIMER


CHAPTER: TWO

SUMMARY


CHAPTER: THREE

OVERVIEW DEFINITION
EPO DRUG BY TYPE BIOLOGICS
Epoietin-alfa Epoietin-beta Darbepoietin-alfa Others
BIOSIMILARS
Epoietin-zeta
Epoietin-omega
Others
APPLICATION
End stage renal disease
Pre-dialysis Oncology Others
SIBE EFFECTS OF ERYTHROPOIETIN




CHAPTER: FOUR

FORECASTING

GLOBAL ERYTHROPOIETIN MARKET Global EPO Biologics Drugs Global EPO Biosimilars Drugs
EPO BIOLOGIC DRUG MARKET BY TYPE Epoietin-alfa
Epoietin-beta Darbepoietin-alfa Others
EPO BIOLOGIC MARKET BY DRUG
Epogen Procrit Eprex Mircera
NeoRecromon
Aranesp
Others
EPO BIOSIMILARS DRUG MARKET BY TYPE Epoetin-zeta
Epoetin-omega

Others

EPO BIOSIMILAR MARKET BY DRUG Retacrit
Binocrit Abseamed EPIAO HEMAX Epoetin-alfa BS Xue Da Sheng Others
EPO DRUG MARKET BY HALF LIFE Long Acting EPO Short Acting EPO
GLOBAL ERYTHROPOIETIN DRUG MARKET BY
APPLICATION

End Stage Renal Disease (ESRD) Oncology Diseases
Pre-dialysis

Others

GLOBAL ERYTHROPOEITIN MARKET SEGMENTATION, BY GEOGRAPHY

North America
Europe

Asia pacific South America ROW
GLOBAL ERYTHROPOEITIN NORTH AMERICAN MARKET SUB-SEGMENTATION

U.S Mexico Canada
GLOBAL ERYTHROPOEITIN EUROPE MARKET SUB-SEGMENTATION

EU-5

Nordic Russia Others
GLOBAL ERYTHROPOEITIN ASIA-PACIFIC MARKET SUB-SEGMENTATION

China India Japan Australia Others
GLOBAL ERYTHROPOEITIN SOUTH AMERICAN MARKET SUB-SEGMENTATION

Brazil Argentina Others


CHAPTER: FIVE

PATENTS AND R & D PIPELINE


CHAPTER: SIX

DRIVERS

INCREASING CASES ESRD

GLOBAL DIALYSIS PATIENT POPULATION
INCREASING PREVALENCE OF CANCER

UPCOMING PATENT EXPIRIES OF ORIGINAL BIO DRUGS

CHAPTER: SEVEN

CHALLENGES

INCREASING CONCERNS OVER RISK OF THROMBOSIS AND PRCA

INCREASING COMPETITION FROM OTHER ALTERNATIVE DRUGS


CHAPTER: EIGHT



SUPPLIERS LANDSCAPE AND COMPANY PROFILES
SUPPLIER LANDSCAPE
COMPANY PROFILES
3S BIO
AMEGA BIOTECH AMGEN
APPOLLO PHARMACEUTICALS ASTRA ZENECA
BEIJING SIHUAN BIOCON (INDIA) BIOSIDUS BLAUSEIGEL
CENTER OF MOLECULAR IMMUNOLOGY CELON LABS
CHALVER LABORATORIES CHENDU DIAO
CJ HEALTH CARE CLARIS LIFESCIENCES CRYOPHARMA
DR. REDDYS LABS EBIOSCIENCE ETHNOR
EMCURE PHARMACEUTICALS FERON LIFESCIENCES
HAYAO BIOLOGICAL HINDUSTAN ANTIBIOTICS HOSPIRA
INCEPTA PHARMACEUTICALS INTAS PHARMACEUTICALS JCR PHARMA
JOHNSON & JOHNSON KISSEI PHARMACEUTICAL KLARVOYANT BIOGENICS KYOWA HAKKO
LANDSTEINER
LA RENON HEALTHCARE LG LIFE SCIENCES INDIA LUPIN
MEDICE ARZNEIMITTEL MICRO LABS
NANOGEN BIOPHARMACEUTICAL NOVARTIS
PANACEA BIOTEC PISA
PROBIOMED
RELIANCE FORMULATION ROCHE
RPG LIFE SCIENCES SEPTALYST LIFESCIENCES SERUM INSTITUTE OF INDIA
SHANDONG KEXING BIOPRODUCTS SHANGHAI CHEMO
SHANTHA BIOTECHNICS STADA ARZENEIMITTEL SUN PHARMACEUTICALS TAJ PHARMACEUTICALS TEVA
VHB LIFE SCIENCES VIFOR PHARMA WOCKHARDT
ZUVENTUS HEALTH CARE ZYDUS CADILA HEALTHCARE
This market research report explain current market for erythropoietin drugs in terms of value. The report also highlights the major drivers and challenges, including their profiles related to erythropoietin drugs.

The global market for erythropoietin drugs has been growing at a CAGR (2015 to 2020) of 1.0% driven by the increasing cases of anemia particularly in kidney diseases and cancer globally.

The global market for erythropoietin drugs is expected to grow from $7.0 billion in 2014 to $7.4 billion in 2015 at a year-on-year (YOY) growth rate of 5.1%. In addition, the market is expected to grow at a five-year CAGR (2015 to 2020) of 1.0%, to reach $7.8 billion in 2020.

The major players in the biologic erythropoietin drug market are, Amgen, Inc., Johnson & Johnson and Hoffmann-LA Roche. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer, Inc.), Biocon, Biosidus, 3SBio, are some of the major biosimilar players across regions.
TABLE: 01 VALUE FORECAST: GLOBAL EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 02 VALUE FORECAST: GLOBAL EPO DRUG MARKET BY CATEGORY, THROUGH 2020 ($ MILLIONS)

TABLE: 03 VALUE FORECAST: GLOBAL EPO DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 04 VALUE FORECAST: GLOBAL EPO DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 05 VALUE FORECAST: GLOBAL EPO DRUG MARKET BY TYPE, THROUGH 2020 ($ MILLIONS)

TABLE: 06 VALUE FORECAST: GLOBAL EPO BIOLOGICS DRUG MARKET BY TYPE, THROUGH 2020 ($ MILLIONS)

TABLE: 07 VALUE FORECAST: GLOBAL EPO BIOSIMILARS DRUG MARKET BY TYPE, THROUGH 2020 ($ MILLIONS)

TABLE: 08 VALUE FORECAST: GLOBAL EPOETIN-ALFA DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 09 VALUE FORECAST: GLOBAL EPOETIN-BETA DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 10 VALUE FORECAST: GLOBAL DARBEPOETIN-ALFA DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 11 VALUE FORECAST: GLOBAL OTHER EPO BIOLOGICS DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 12 VALUE FORECAST: GLOBAL EPOETIN-ALFA DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 13 VALUE FORECAST: GLOBAL EPOETIN-BETA DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 14 VALUE FORECAST: GLOBAL DARBEPOETIN-ALFA DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 15 VALUE FORECAST: GLOBAL OTHER BIOLOGIC DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 16 VALUE FORECAST: GLOBAL BIOLOGIC MARKET BY DRUG, THROUGH 2020 ($ MILLIONS)

TABLE: 17 VALUE FORECAST: GLOBAL EPOGEN DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 18 VALUE FORECAST: GLOBAL EPOGEN DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 19 VALUE FORECAST: GLOBAL PROCRIT DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 20 VALUE FORECAST: GLOBAL PROCRIT DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 21 VALUE FORECAST: GLOBAL EPREX DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 22 VALUE FORECAST: GLOBAL EPREX DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 23 VALUE FORECAST: GLOBAL ARANESP DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 24 VALUE FORECAST: GLOBAL ARANESP DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 25 VALUE FORECAST: GLOBAL NEORECORMON DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 26 VALUE FORECAST: GLOBAL NEORECORMON DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 27 VALUE FORECAST: GLOBAL MIRCERA DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 28 VALUE FORECAST: GLOBAL MIRCERA DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 29 VALUE FORECAST: GLOBAL EPOETIN-ZETA DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 30 VALUE FORECAST: GLOBAL EPOETIN-OMEGA DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 31 VALUE FORECAST: GLOBAL OTHER EPO BIOSIMILARS DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 32 VALUE FORECAST: GLOBAL EPOETIN-ZETA DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 33 VALUE FORECAST: GLOBAL EPOETIN-OMEGA DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 34 VALUE FORECAST: GLOBAL OTHER BIOSIMILARS DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 35 VALUE FORECAST: GLOBAL BIOSIMILARS MARKET BY DRUG, THROUGH 2020 ($ MILLIONS)

TABLE: 36 VALUE FORECAST: GLOBAL RETACRIT DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 37 VALUE FORECAST: GLOBAL RETACRIT DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 38 VALUE FORECAST: GLOBAL BINOCRIT DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 39 VALUE FORECAST: GLOBAL BINOCRIT DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 40 VALUE FORECAST: GLOBAL ABSEAMED DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 41 VALUE FORECAST: GLOBAL ABSEAMED DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 42 VALUE FORECAST: GLOBAL EPIAO DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 43 VALUE FORECAST: GLOBAL EPIAO DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 44 VALUE FORECAST: GLOBAL HEMAX DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 45 VALUE FORECAST: GLOBAL HEMAX DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 46 VALUE FORECAST: GLOBAL EPOETIN-ALFA BS DRUG MARKETBY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 47 VALUE FORECAST: GLOBAL EPOETIN-ALFA BS DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 48 VALUE FORECAST: GLOBAL XUE DA SHENG DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 49 VALUE FORECAST: GLOBAL XUE DA SHENG DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 50 VALUE FORECAST: GLOBAL BINOCRIT DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 51 VALUE FORECAST: GLOBAL BINOCRIT DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 52 VALUE FORECAST: GLOBAL EPO DRUG MARKET BY HALF-LIFE, THROUGH 2020 ($ MILLIONS)

TABLE: 53 VALUE FORECAST: GLOBAL LONG ACTING EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 54 VALUE FORECAST: GLOBAL SHORT ACTING EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 55 VALUE FORECAST: GLOBAL LONG ACTING EPO DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 56 VALUE FORECAST: GLOBAL SHORT ACTING EPO DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 57 VALUE FORECAST: GLOBAL LONG ACTING EPO DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 58 VALUE FORECAST: GLOBAL SHORT ACTING EPO DRUG MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)

TABLE: 59 VALUE FORECAST: GLOBAL EPO BIOLOGICS DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 60 VALUE FORECAST: GLOBAL EPO BIOSIMILARS DRUG MARKET BY APPLICATIONS, THROUGH 2020 ($ MILLIONS)

TABLE: 61 VALUE FORECAST: GLOBAL END STAGE RENAL DISEASE (ESRD) APPLICATION DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 62 VALUE FORECAST: GLOBAL PRE-DIALYSIS APPLICATION DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 63 VALUE FORECAST: GLOBAL ONCOLOGY APPLICATION DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 64 VALUE FORECAST: GLOBAL OTHER APPLICATION DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 65 VALUE FORECAST: GLOBAL EPO BIOLOGICS DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 66 VALUE FORECAST: GLOBAL EPO BIOSIMILARS DRUG MARKET BY REGION, THROUGH 2020 ($ MILLIONS)

TABLE: 67 VALUE FORECAST: NORTH AMERICA EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 68 VALUE FORECAST: NORTH AMERICA EPO BIOLOGIC DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 69 VALUE FORECAST: NORTH AMERICA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 70 VALUE FORECAST: MEXICO EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 71 VALUE FORECAST: EUROPE EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 72 VALUE FORECAST: EUROPE EPO BIOLOGIC DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 73 VALUE FORECAST: EUROPE EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 74 VALUE FORECAST: GERMANY EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 75 VALUE FORECAST: ITALY EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 76 VALUE FORECAST: FRANCE EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 77 VALUE FORECAST: SPAIN EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 78 VALUE FORECAST: U.K. EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 79 VALUE FORECAST: NORDIC EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 80 VALUE FORECAST: RUSSIA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 81 VALUE FORECAST: OTHER EUROPEAN EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 82 VALUE FORECAST: ASIA-PACIFIC EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 83 VALUE FORECAST: ASIA-PACIFIC EPO BIOLOGIC DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 84 VALUE FORECAST: ASIA-PACIFIC EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 85 VALUE FORECAST: CHINA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 86 VALUE FORECAST: INDIA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 87 VALUE FORECAST: JAPAN EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 88 VALUE FORECAST: AUSTRALIA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 89 VALUE FORECAST: OTHER ASIA-PACIFIC EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 90 VALUE FORECAST: SOUTH AMERICA EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 91 VALUE FORECAST: SOUTH AMERICA EPO BIOLOGIC DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 92 VALUE FORECAST: SOUTH AMERICA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 93 VALUE FORECAST: BRAZIL EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 94 VALUE FORECAST: ARGENTINA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 95 VALUE FORECAST: OTHER SOUTH AMERICA EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 96 VALUE FORECAST: ROW EPO DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 97 VALUE FORECAST: ROW EPO BIOLOGIC DRUG MARKET, THROUGH 2020 ($ MILLIONS)

TABLE: 98 VALUE FORECAST: ROW EPO BIOSIMILAR DRUG MARKET, THROUGH 2020 ($ MILLIONS)
FIGURE: 01 MARKET SHARE BY VALUE: GLOBAL EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 02 MARKET SHARE BY VALUE: GLOBAL EPO DRUG MARKET BY CATEGORY, 2015 AND 2020 (%)

FIGURE: 03 MARKET SHARE BY VALUE: GLOBAL EPO DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 04 MARKET SHARE BY VALUE: GLOBAL EPO DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 05 MARKET SHARE BY VALUE: GLOBAL EPO DRUG MARKET BY TYPE, 2015 AND 2020 (%)

FIGURE: 06 MARKET SHARE BY VALUE: GLOBAL EPO BIOLOGICS DRUG MARKET BY TYPE, 2015 AND 2020 (%)

FIGURE: 07 MARKET SHARE BY VALUE: GLOBAL EPO BIOSIMILARS DRUG MARKET BY TYPE, 2015 AND 2020 (%)

FIGURE: 08 MARKET SHARE BY VALUE: GLOBAL EPOETIN-ALFA DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 09 MARKET SHARE BY VALUE: GLOBAL EPOETIN-BETA DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 10 MARKET SHARE BY VALUE: GLOBAL DARBEPOETIN-ALFA DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 11 MARKET SHARE BY VALUE: GLOBAL OTHER EPO BIOLOGICS DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 12 MARKET SHARE BY VALUE: GLOBAL EPOETIN-ALFA DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 13 MARKET SHARE BY VALUE: GLOBAL EPOETIN-BETA DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 14 MARKET SHARE BY VALUE: GLOBAL DARBEPOETIN-ALFA DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 15 MARKET SHARE BY VALUE: GLOBAL OTHER BIOLOGIC DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 16 MARKET SHARE BY VALUE: GLOBAL BIOLOGIC MARKET BY DRUG, 2015 AND 2020 (%)

FIGURE: 17 MARKET SHARE BY VALUE: GLOBAL EPOGEN DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 18 MARKET SHARE BY VALUE: GLOBAL EPOGEN DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 19 MARKET SHARE BY VALUE: GLOBAL PROCRIT DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 20 MARKET SHARE BY VALUE: GLOBAL PROCRIT DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 21 MARKET SHARE BY VALUE: GLOBAL EPREX DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 22 MARKET SHARE BY VALUE: GLOBAL EPREX DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 23 MARKET SHARE BY VALUE: GLOBAL ARANESP DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 24 MARKET SHARE BY VALUE: GLOBAL ARANESP DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 25 MARKET SHARE BY VALUE: GLOBAL NEORECORMON DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 26 MARKET SHARE BY VALUE: GLOBAL NEORECORMON DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 27 MARKET SHARE BY VALUE: GLOBAL MIRCERA DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 28 MARKET SHARE BY VALUE: GLOBAL MIRCERA DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 29 MARKET SHARE BY VALUE: GLOBAL EPOETIN-ZETA DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 30 MARKET SHARE BY VALUE: GLOBAL EPOETIN-OMEGA DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 31 MARKET SHARE BY VALUE: GLOBAL OTHER EPO BIOSIMILARS DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 32 MARKET SHARE BY VALUE: GLOBAL EPOETIN-ZETA DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 33 MARKET SHARE BY VALUE: GLOBAL EPOETIN-OMEGA DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 34 MARKET SHARE BY VALUE: GLOBAL OTHER BIOSIMILARS DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 35 MARKET SHARE BY VALUE: GLOBAL BIOSIMILARS MARKET BY DRUG, 2015 AND 2020 (%)

FIGURE: 36 MARKET SHARE BY VALUE: GLOBAL RETACRIT DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 37 MARKET SHARE BY VALUE: GLOBAL RETACRIT DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 38 MARKET SHARE BY VALUE: GLOBAL BINOCRIT DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 39 MARKET SHARE BY VALUE: GLOBAL BINOCRIT DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 40 MARKET SHARE BY VALUE: GLOBAL ABSEAMED DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 41 MARKET SHARE BY VALUE: GLOBAL ABSEAMED DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 42 MARKET SHARE BY VALUE: GLOBAL EPIAO DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 43 MARKET SHARE BY VALUE: GLOBAL EPIAO DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 44 MARKET SHARE BY VALUE: GLOBAL HEMAX DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 45 MARKET SHARE BY VALUE: GLOBAL HEMAX DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 46 MARKET SHARE BY VALUE: GLOBAL EPOETIN-ALFA BS DRUG MARKETBY REGION, 2015 AND 2020 (%)

FIGURE: 47 MARKET SHARE BY VALUE: GLOBAL EPOETIN-ALFA BS DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 48 MARKET SHARE BY VALUE: GLOBAL XUE DA SHENG DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 49 MARKET SHARE BY VALUE: GLOBAL XUE DA SHENG DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 50 MARKET SHARE BY VALUE: GLOBAL BINOCRIT DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 51 MARKET SHARE BY VALUE: GLOBAL BINOCRIT DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 52 MARKET SHARE BY VALUE: GLOBAL EPO DRUG MARKET BY HALF-LIFE, 2015 AND 2020 (%)

FIGURE: 53 MARKET SHARE BY VALUE: GLOBAL LONG ACTING EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 54 MARKET SHARE BY VALUE: GLOBAL SHORT ACTING EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 55 MARKET SHARE BY VALUE: GLOBAL LONG ACTING EPO DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 56 MARKET SHARE BY VALUE: GLOBAL SHORT ACTING EPO DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 57 MARKET SHARE BY VALUE: GLOBAL LONG ACTING EPO DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 58 MARKET SHARE BY VALUE: GLOBAL SHORT ACTING EPO DRUG MARKET BY APPLICATION, 2015 AND 2020 (%)

FIGURE: 59 MARKET SHARE BY VALUE: GLOBAL EPO BIOLOGICS DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 60 MARKET SHARE BY VALUE: GLOBAL EPO BIOSIMILARS DRUG MARKET BY APPLICATIONS, 2015 AND 2020 (%)

FIGURE: 61 MARKET SHARE BY VALUE: GLOBAL END STAGE RENAL DISEASE (ESRD) APPLICATION DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 62 MARKET SHARE BY VALUE: GLOBAL PRE-DIALYSIS APPLICATION DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 63 MARKET SHARE BY VALUE: GLOBAL ONCOLOGY APPLICATION DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 64 MARKET SHARE BY VALUE: GLOBAL OTHER APPLICATION DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 65 MARKET SHARE BY VALUE: GLOBAL EPO BIOLOGICS DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 66 MARKET SHARE BY VALUE: GLOBAL EPO BIOSIMILARS DRUG MARKET BY REGION, 2015 AND 2020 (%)

FIGURE: 67 MARKET SHARE BY VALUE: NORTH AMERICA EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 68 MARKET SHARE BY VALUE: NORTH AMERICA EPO BIOLOGIC DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 69 MARKET SHARE BY VALUE: NORTH AMERICA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 70 MARKET SHARE BY VALUE: MEXICO EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 71 MARKET SHARE BY VALUE: EUROPE EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 72 MARKET SHARE BY VALUE: EUROPE EPO BIOLOGIC DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 73 MARKET SHARE BY VALUE: EUROPE EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 74 MARKET SHARE BY VALUE: GERMANY EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 75 MARKET SHARE BY VALUE: ITALY EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 76 MARKET SHARE BY VALUE: FRANCE EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 77 MARKET SHARE BY VALUE: SPAIN EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 78 MARKET SHARE BY VALUE: U.K. EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 79 MARKET SHARE BY VALUE: NORDIC EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 80 MARKET SHARE BY VALUE: RUSSIA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 81 MARKET SHARE BY VALUE: OTHER EUROPEAN EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 82 MARKET SHARE BY VALUE: ASIA-PACIFIC EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 83 MARKET SHARE BY VALUE: ASIA-PACIFIC EPO BIOLOGIC DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 84 MARKET SHARE BY VALUE: ASIA-PACIFIC EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 85 MARKET SHARE BY VALUE: CHINA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 86 MARKET SHARE BY VALUE: INDIA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 87 MARKET SHARE BY VALUE: JAPAN EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 88 MARKET SHARE BY VALUE: AUSTRALIA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 89 MARKET SHARE BY VALUE: OTHER ASIA-PACIFIC EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 90 MARKET SHARE BY VALUE: SOUTH AMERICA EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 91 MARKET SHARE BY VALUE: SOUTH AMERICA EPO BIOLOGIC DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 92 MARKET SHARE BY VALUE: SOUTH AMERICA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 93 MARKET SHARE BY VALUE: BRAZIL EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 94 MARKET SHARE BY VALUE: ARGENTINA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 95 MARKET SHARE BY VALUE: OTHER SOUTH AMERICA EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 96 MARKET SHARE BY VALUE: ROW EPO DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 97 MARKET SHARE BY VALUE: ROW EPO BIOLOGIC DRUG MARKET, 2015 AND 2020 (%)

FIGURE: 98 MARKET SHARE BY VALUE: ROW EPO BIOSIMILAR DRUG MARKET, 2015 AND 2020 (%)

Download Sample

Just fill the short form below to get the sample

Don’t like forms? Give us a call. U.S. +1(973)805-7440 (International) Email us at: amit@ceskaa.com